Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Intrahepatic cholestasis]

Y Adachi1, T Kamisako

  • 1Second Department of Internal Medicine, Kinki University School of Medicine, Japan.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two cases of histopathologically advanced (stage IV) early gastric cancers.

Tumori·2001
Same author

Characterization of ATP-dependent monoglucuronosyl bilirubin transport across rat canalicular membrane vesicles.

Hepatology research : the official journal of the Japan Society of Hepatology·2001
Same author

Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance.

Journal of gastroenterology·2000
Same author

Repeated hepatic arterial chemoembolization therapy for management of a patient with metastatic carcinoid tumors of the liver.

The American journal of gastroenterology·2000
Same author

Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family.

Advances in enzyme regulation·2000
Same author

Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver.

Gastroenterology·1999
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

This review examines how cholestatic drugs, bile acids, and estrogens affect hepatocyte membranes and transport systems, impacting liver function in cholestatic diseases. Understanding these interactions is key to developing targeted therapies for liver conditions.

Area of Science:

  • Hepatology and membrane transport.
  • Endocrinology and drug interactions.
  • Gastroenterology and liver disease mechanisms.

Context:

  • Cholestatic diseases involve impaired bile flow, leading to liver damage.
  • Hepatocyte plasma membranes and their transporters are crucial for bile acid homeostasis.
  • Various endogenous and exogenous compounds influence these membrane functions.

Purpose:

  • To review the effects of cholestatic drugs, bile acids, and estrogens on hepatocyte membranes.
  • To explore alterations in membrane transporters during cholestatic conditions.
  • To discuss the mechanisms underlying drug-induced cholestasis and related liver diseases.

Summary:

  • Cyclosporin A inhibits bile salt transporter (BST), while ethynylestradiol affects glutathione excretion.

Related Experiment Videos

  • Estrogens and bile acids like taurochenodeoxycholic acid interact with transport systems, potentially causing cholestasis.
  • Defective biliary excretion and reduced transporter function (BST, MOAT) are implicated in Byler disease, septic, and obstructive cholestasis.

    • Impact:

    • Provides insights into the molecular mechanisms of cholestasis.
    • Highlights the role of specific transporters and signaling pathways in liver disease.
    • Informs the development of novel therapeutic strategies for cholestatic liver disorders.